Peer Exchange

Panelists discuss how recent advancements in treatment strategies for ALK-positive and BRAF-positive V600E NSCLC, including efficacy updates and the management of brain metastases, can enhance personalized care and optimize patient outcomes.

This series delves into recent advancements in the treatment of advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC), focusing on clinical trial findings from FLAURA2, ADAURA, TROPION-Lung01, and HERTHENA-Lung01 and their implications for optimizing patient management and survival outcomes.

Panelists discuss how recent advancements in frontline and second-line therapies for unrespectable hepatocellular carcinoma (uHCC) are reshaping treatment strategies and improving patient outcomes.

In this OncLive Peer Exchange series, a panel of experts discusses the latest advancements in the management of gynecological cancers, highlighting updates from ESMO 2024, including treatment paradigms for advanced ovarian, cervical, and endometrial cancers, biomarker testing strategies, and emerging therapies such as antibody-drug conjugates.

Panelists discuss how recent clinical trials and innovative therapies are reshaping the treatment landscape for small cell lung cancer, emphasizing the importance of personalized approaches and multidisciplinary strategies to improve patient outcomes.

Elias Jabbour, MD; Evandro D. Bezerra, MD; Lori Muffly, MD; Jae H. Park, MD, and Gregory W. Roloff, MD,review the role of CAR T-cell therapy\ for relapsed/refractory acute lymphoblastic leukemia, address adverse event management and supportive care, and highlight significant updates presented at the American Society of Clinical Oncology and European Hematology Association 2024 conferences.

Catherine C. Coombs, MD, Matthew S. Davids, MD, MMSc; Richardo D. Parrondo, MD; Nicole Lamanna, MD, and Alexey Danilov, MD, PhD, examine treatment approaches for newly diagnosed chronic lymphocytic leukemia (CLL), including BTK inhibitor therapy, management of adverse events, and strategies for relapsed/refractory CLL.

Five medical provide insights around breakthrough treatment strategies in relapsed/recurrent DLBCL.

John Marshall, MD; Al B. Benson III, MD, FACP, FACCC, FASCO; Kristen Ciombor, MD, MSCI; Stacey Cohen, MD, and Marwan Fakih, MD, examine the landscape of second-line and third-line treatments for metastatic colorectal cancer, along with recent advancements in managing the disease.

Vijayakrishna Gadi, MD, PhD, sets the stage for a discussion around HER2-directed ADCs in the solid tumor space.

Led by Sandip P. Patel, MD, key opinion leaders address key updates in treatment strategies and management of stage III NSCLC.

Guillermo Garcia-Manero, MD; Rami Komrokji, MD; Esther Natalie Oliva, MD; Amer Zeidan, MBBS, MHS, and Dr Thomas Cluzeauprovide expert insights on the latest developments in Lower-Risk Myelodysplastic Syndromes (LR-MDS) as presented at the European Hematology Association (EHA) 2024 conference.

Medical experts in small cell lung cancer convene to examine first-line treatments, ongoing clinical trials, and emerging therapies shaping the evolving treatment landscape.

A panel of medical experts reviews the latest advances in managing and treating renal cell carcinoma (RCC) and non-clear cell renal cell carcinoma (nccRCC), discussing recent trial data and sharing insights from their clinical practices.

Mark Socinski, MD; Helena A. Yu, MD; Zosia Piotrowska, MD, MHS; Julia Rotow, MD, and Benjamin Levy, MD,discuss the current standard of care, emerging data on novel therapies such as antibody-drug conjugates (ADCs) and clinical trials, patient selection considerations, and practical guidance foroptimizing patient care.

Kelly McCann, MD, PhD, drives a discussion surrounding key topics and highlights in HR+ breast cancer treatment as presented at ASCO 2024.

A panel of experts on HER2+ breast cancer has a comprehensive discussion on recent data updates and how they might impact clinical practice.

Lori Wirth, MD, moderates a panel of medical experts specializing in radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC), discussing current treatments and ongoing clinical trials in this field.

A panel of experts on colorectal cancer provides comprehensive insights on MRD testing within the disease space, highlight the general landscape, recent data, ongoing trials, and future directions.